Myovant Sciences Stock News

Millennium Management LLC lifted its position in shares of Myovant Sciences Ltd. (NYSE:MYOV) by 1,467.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 219,459 shares of the companys stock after buying an additional 205,459 shares during the period. Millennium Management LLCs holdings in Myovant Sciences were worth []

BASEL, Switzerland, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the Evercore ISI 4th

BASEL, Switzerland, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021. David Marek, Chief Executive Officer of Myovant Sciences, Inc. will participate in a fireside chat at 11:45 a.m. Eastern Time.

Equities research analysts expect Myovant Sciences Ltd. (NYSE:MYOV) to post earnings per share of ($0.56) for the current quarter, according to Zacks. Three analysts have made estimates for Myovant Sciences’ earnings, with the lowest EPS estimate coming in at ($0.64) and the highest estimate coming in at ($0.50). Myovant Sciences reported earnings per share of […]

Equities analysts expect that Myovant Sciences Ltd. (NYSE:MYOV) will announce earnings per share (EPS) of ($0.56) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Myovant Sciences earnings, with estimates ranging from ($0.64) to ($0.50). Myovant Sciences posted earnings of ($0.82) per share in the same quarter last year, which []

Myovant Sciences Ltd. (NYSE:MYOV)s traded shares stood at 0.4 million during the last session, with the companys beta value hitting 2.73. At the close of trading, the stocks price was $20.24, to imply a decrease of -0.93% or -$0.19 in intraday trading. The MYOV shares 52-week high remains $30.90, putting it -52.67% down since that Boom Or Bust: What Is Next For Myovant Sciences Ltd. (NYSE: MYOV) Stock? Read More »

Relugolix is approved and launched in two indications and could establish itself as a new Standard of Care. The inked 4.2 billion deal with top-class partner Pfizer verifies the blockbuster potential

Myovant Sciences (MYOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Tucked in its Q2 earnings release, Myovant Sciences Ltd (NYSE: MYOV) said that Pfizer Inc (NYSE: PFE) has notified its option decision for international rights to relugolix in oncology. Pfizer dec

Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q2 2021 Results - Earnings Call Transcript

BASEL, Switzerland and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the presentation of new data from clinical studies of its

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion

BASEL, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and

RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia